On-Demand Presentation

Need more clarity with your chromatography? This will PEEK your interest

Discover advances in biomolecule analysis and learn how to improve data quality, sensitivity and resolution for metal sensitive molecules.

By watching this presentation, you will learn key strategies for:

  • Advances in biomolecule analysis
  • How you can improve data quality, sensitivity and resolution for metal-sensitive molecules (for small molecule and large biotherapeutic analysis)
  • Advanced data processing technology for characterizing oligonucleotide products and impurities for LC-MS datasets

Event Overview

The shift towards biopharmaceuticals during the last decade posed some challenges in the construction of modern liquid chromatography systems, particularly addressing the problem of non-specific interactions, making the development of reproducible analytical methods a challenge.

This presentation covers and discusses the latest advances in liquid chromatography technology to minimize the effect of non-specific interactions. The discussion ranges from the basics of 'metal-sensitive' molecules to the method development strategies for the analysis of biomolecules. We provide a comprehensive overview of the major analytical challenges that could be faced when an accurate analysis is required for 'metal-sensitive' compounds, and we discuss the best countermeasures that can be adopted to ensure 'method robustness'. Moreover, we describe efficient data processing solutions for the characterization of oligonucleotide products and impurities for LC-MS datasets.

What you need to know:

Format: On-demand

Duration: Approximately 25 minutes


Raymond Wong, MChem, Ph.D., MRSC
Senior Product Manager and National Sales Manager, Shimadzu UK Limited

Raymond Wong has over 20 years’ experience working within the analytical, purification and pharmaceutical industry. Dr Wong started as a synthetic organic chemist where early projects included investigating new fluorinated compounds with Ineos Fluor for early OLED technology. He was later involved with synthesising modified oligonucleotides for antisense therapeutics, before transitioning to producing dynamic combinatorial libraries to investigate Sequencing by Synthesis (SbS). Following several diverse pharma campaigns within a contract laboratory, Raymond moved to Phenomenex to support method development across different sectors before joining Shimadzu over 8 years ago allowing him to collaborate with people looking to progress their research.


The information you provide will be shared with the sponsors of this content. Separation Science or its sponsors may contact you to offer you content or products based on your interest in this topic. You may unsubscribe from these communications at any time. For information on how to unsubscribe, our privacy practices, and commitment to protecting your privacy, check out our Privacy Policy.